版本:
中国

AbbVie's rheumatoid arthritis drug succeeds in late-stage trial

June 7 U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study.

Two doses of the drug, upadacitinib, were compared against a placebo in the 12-week long study, AbbVie said. (Reporting by Divya Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐